Researchers at Penn Medicine have uncovered how psilocybin, the main psychoactive ingredient in certain “magic mushrooms,” influences key brain circuits, offering potential new approaches for treating chronic pain and related mental health conditions.

Chronic pain affects more than 1.5 billion people globally and often intertwines with anxiety and depression, creating a feedback loop that worsens both physical and emotional suffering. The new research from the Perelman School of Medicine at the University of Pennsylvania, published in Nature Neuroscience, sheds light on how this cycle might be broken.

“As an anesthesiologist, I frequently care for people undergoing surgery who suffer from both chronic pain and depression. In many cases, they’re not sure which condition came first, but often, one makes the other worse,” said Joseph Cichon, MD, PhD, an assistant professor of Anesthesiology and Critical Care at Penn and senior author of the study. “This new study offers hope. These findings open the door to developing new, non-opioid, non-addictive therapies as psilocybin and related psychedelics are not considered addictive.”

Targeting the Brain’s Pain and Mood Hub
In experiments using mice with chronic nerve injury and inflammatory pain, scientists discovered that a single psilocybin dose eased both pain and depression-like behaviors caused by that pain, with the effects lasting for nearly two weeks. Psilocybin achieves this by subtly stimulating serotonin receptors (5-HT2A and 5-HT1A) in the brain. “Unlike other drugs that fully turn these signals on or off, psilocybin acts more like a dimmer